The FDA has provided a long-awaited approval for Cephalon's Nuvigil, a new version of its sleep disorder drug Provigil. Final approval had hit a snag with the agency's delays related to describing the drug's side effects on the drug label. Cephalon says it is in no hurry to start marketing the drug. It will await the arrival of more clinical data and won't start selling the therapy this year. Report